Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Shulei Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing 211198, China. Hauptthemen laut MEDLINE: Antiviral Agents, Coronavirus OC43, Human, Indoles, Peptidomimetics. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Hubei Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
A series of novel Mpro inhibitors was designed and synthesized to combat the coronavirus, such as HCoV-OC43 and SARS-CoV-2, and several compounds showed comparable antiviral activity to nirmatrelvir. Among them, an octahydroindole-based peptidomimetic covalent inhibitor 28f showed strong inhibitory activity against Mpros and exhibited broad-spectrum anticoronavirus activity with EC50 values ranging from 0.027 to 4.41 μM. Besides, this compound displayed potent antiviral activity against EV71. Compared to FB2001, 28f displayed better pharmacokinetic properties, and the value of oral bioavailability in CD-1 mice and Beagle dogs was improved to 10.4 and 10.2%, respectively. In addition, oral treatment with 28f could significantly reduce the viral loads of HCoV-OC43 in mice, and compound 28f could also effectively reduce lung viral loads in a K18-hACE2 transgenic mouse model without ritonavir. Taken together, compound 28f is a promising orally bioavailable broad-spectrum antiviral drug candidate that deserves further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China.
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, Hubei, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Lingang Laboratory, Shanghai 200031, China.
ORCID-Profile: Jiang Wang, Yechun Xu, Leike Zhang, Hong Liu
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Hubei Province
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Hu, S., Zhang, Y., Wang, C., Li, J., Su, H., Xie, X., Wang, J., Wang, J., Cao, J., He, X., Xu, Y., Zhang, L., Dai, W., & Liu, H. (2025). Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03024
Vancouver
Hu S, Zhang Y, Wang C, Li J, Su H, Xie X, et al. Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03024
BibTeX
@article{Hu2025,
author = {Hu, Shulei and Zhang, Yumin and Wang, Chenchen and Li, Jian and Su, Haixia and Xie, Xiong and Wang, Jiang and Wang, Jinlin and Cao, Junyuan and He, Xiaofei and Xu, Yechun and Zhang, Leike and Dai, Wenhao and Liu, Hong},
title = {Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03024}
}
EUVIMED